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Abstract 
There are major variations in the susceptibility to weight gain among individuals under 
similar external influences (decreased physical activity and excessive calorie intake), 
depending on the genetic background. In the present study, we performed a microarray 
analysis and RT-PCR validations in order to find out differential gene expression in 
subcutaneous abdominal adipose tissue from two groups of subjects that despite living 
in similar environmental conditions such as a habitual high fat dietary intake (energy as 
fat >40%) and similar moderate physical activity, some of them were successfully 
“resistant” (lean) to weight gain, while others were “susceptible” to fat deposition 
(obese). The classification of up- and down- regulated genes into different categories 
together with the analysis of the altered biochemical pathways, revealed a coordinated 
downregulation of catabolic pathways operating in the mitochondria: fatty acid 
oxidation (P=0.008), TCA cycle (P=0.001) and electron transport chain (P=0.012). At 
the same time, glucose metabolism (P=0.010) and fatty acid biosynthesis (P=0.011) 
pathways were also downregulated in obese compared to lean subjects. In conclusion, 
our data showed an orchestrated downregulation of nuclear-encoded mitochondrial gene 
expression. These genes are involved in cellular respiration and oxidative metabolism 
pathways, and could play a role in the susceptibility to weight gain in some individuals. 
 
Keywords: Obesity; Genetic susceptibility; High fat diet; Metabolic pathways; 
Microarray. 
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Introduction 
Obesity is a major health problem in the developed world and an increasing problem in 
low income countries (38). Obesity is strongly associated with different illnesses such 
as type 2 diabetes and cardiovascular diseases (14, 23). Increasing prevalence of obesity 
has been proposed to be a consequence of both increased energy availability and 
reduced energy expenditure superimposed on a genetic background evolved for survival 
in conditions of food deprivation (30). A number of studies have demonstrated that 
white adipose tissue (WAT) is a very active endocrine organ, which secretes important 
molecules involved in the regulation of body weight and insulin sensitivity (1, 17). 
Moreover, it has been reported the important contribution of WAT to the control of 
energy homeostasis with the study of tissue-specific knockout models and the discovery 
of adipocyte-specific secreted factors that have powerful effects on fuel metabolism (6, 
39).  
Excess of dietary fat has been implicated in the development of obesity and diabetes (5, 
35). However, there are large interindividual differences in this compensatory response 
to increased fat intake. A recent study has evidenced that major changes in the genome 
of individual animals may be established prior to the introduction of a high-fat diet (19). 
In a previous study, we recruited two groups of subjects who lived in similar conditions 
of habitual high-fat dietary intake and moderate physical activity (during at least the 3 
last years). Despite living in a condition of chronic disturbance of metabolic 
homeostasis, the group of lean volunteers was successfully 'resistant' (lean) to weight 
gain (25), as previously shown in rats (33).  
Given the fact that current nutritional habits and lifestyles of most modern humans 
heavily favour metabolic overload with diminishing physical activity, the goal of this 
study was focused on unveiling the involvement of specific WAT genes related to 
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energy utilization in excessive weight gain in presumably predisposed subjects. For this 
purpose, we applied high density oligonucleotide arrays, a powerful tool (22, 29) to 
identify and compare patterns of genes differentially expressed in subcutaneous 
abdominal adipose tissue (WAT) from these two groups of subjects with different 
susceptibility to weight gain when consuming high-fat diets. 
 
Subjects and methods 
Study design and Subjects  
Nine lean and nine obese high fat consumers were recruited (range, 22-33 years old for 
lean and 21-35 years old for the obese group), as previously described, using a validated 
questionnaire based on self-reported questions about lifestyle and food frequency 
consumption (25). All subjects were healthy male, non-diabetic, non-hyperlipidemic, 
taking no oral medications and with a stable body weight during at least the previous 3 
months. In order to confirm that the amount and composition of energy ingested was 
>40% from fat, each subject completed a 3 day weighed food record for two weekdays 
and one weekend day. The food records were analysed with a computerized program 
(Medisystem, SanoCare, Madrid, Spain) by a trained nutritionist. To quantify the level 
of physical activity (PA), each participant completed a validated questionnaire (27) 
based on self reported questions about their leisure time and their work-time physical 
activities on a typical work day and on a typical weekend day. In addition, sedentary 
lifestyle was assessed through the number of hours spent sitting down per week 
(watching TV or videos, reading or listening to music, etc.) on a typical work day and 
on a typical weekend day. All the volunteers remained living in the same conditions 
during at least the last three years.  
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Anthropometric measurements and adipose tissue biopsy 
On the experimental day, volunteers arrived at the Clinica Universidad de Navarra after 
12 hours of overnight fast. Anthropometric measurements were made by standard 
procedures as previously described (25). Then, biopsies (1-2 grams) of subcutaneous 
abdominal adipose tissue (WAT) were performed by liposuction under local 
anaesthesia. The samples were washed and soaked in RNA-later (Qiagen, Valencia, 
California) to avoid RNA degradation and then stored at -80 ºC until utilization. The 
protocol was approved by the Ethical Committee of the University of Navarra at the 
Clinica Universidad de Navarra, and all subjects gave their written informed consent 
before participating in the study. 
RNA preparation  
Total RNA was isolated from each human WAT sample (including adipocytes and 
stroma-vascular fraction) by homogenization with an ultra-turrax® T 25 basic using 
TRIzol (Life Technologies, Gaithersburg, MD) according to the manufacturer’s 
instructions and incubated with RNase-free DNase (Ambion, Austin, TX) for 30 min at 
37°C. RNA concentration was measured spectrophotometrically and its quality was 
verified by ethidium bromide staining after agarose gel electrophoresis.  
Microarray experiments and analysis 
RNA was pooled to minimize the biological variation between the individual lean and 
obese subjects. Thus, 15 micrograms of total RNA from two pools of 3 lean subjects 
each (L1 and L2) and two other from 3 obese individuals each (O1 and O2) were used 
in the standard protocol from Affymetrix to label targets. These targets (biotinylated 
complementary RNA) were hybridized to the Human HG-U133 A GeneChip arrays 
(Affymetrix; Santa Clara, CA) at Progenika Biopharma Inc (Bilbao, Spain), using tools 
obtained from Affymetrix and according to the manufacturer’s protocol (Affymetrix, 
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Santa Clara, CA). Thus, a total of 4 array hybridizations were performed. The obtained 
signal values were further analyzed with the Affymetrix microarray suite 5.0. software 
(MAS 5.0) system to examine obesity-dependent increases and decreases in gene 
expression. After global scaling, the signal detection, the signal low ratio (SLR) and the 
different call change were calculated and compared between GeneChips. The 
comparison was performed for all four combinations: obese vs. lean samples; O1 vs. 
L1, O1 vs. L2; O2 vs. L1; O2 vs. L2 in a double-cross analysis (concordance analysis). 
The alteration ratios of the gene expression were represented as means of SLR of the 
four quotients.  
The "change call" criteria of Affymetrix software for several known genes related to 
obesity matched a call change value of 75% ("increase": leptin; "decrease": 
adiponectin). These changes were verified by real-time PCR (24). For this reason, as 
cutoff value, concordance in the different call change of 75% or more was chosen in the 
indications of “increase” and “decrease” for changes in gene expression, as previously 
described (7). 
Identification of altered pathways  
The ultimate goal of identifying genes that were differentially expressed in obese 
compared to lean high fat intakers was to determine whether any of these genes 
appeared to be part of the same pathway. The approach taken was to use GARBAN 
software (26, 36) to classify the differentially expressed genes according to KEGG 
(Kyoto Encyclopedia of Genes and Genomes) and GO biological process criteria. 
Furthermore, an enrichment analysis was performed using the WebGestalt system (40), 
which uses the hypergeometric test to identify those pathways in which the number of 
identified genes exceeded the number expected (P<0.05); Up and downregulated genes 
were analyzed separately. 
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Real-time PCR analysis  
Differential gene expression was further confirmed by real-time PCR of a subset of 
genes in individual samples (n=9 in each group). Reagents for real-time PCR analysis of 
ACADM, ALDH1L1, ETFDH, HADHSC, FASN, SCD and 18S (Assays-on-Demand, 
TaqMan Reverse Transcriptase reagents, and TaqMan Universal PCR Master mix) were 
purchased from Applied Biosystems (Foster City, CA) and the conditions were used 
according to the manufacturer's protocol. Amplification and detection of specific 
products were performed with the ABI PRISM 7000HT system (Applied Biosystems). 
Human 18S was used as reference to normalize the expression levels between samples 
allowing data to be expressed relative to 18S rRNA, therefore compensating for any 
differences in reverse transcriptase efficacy, as previously described (24). 
Statistical analysis.  
Data are expressed as means ± SE (n=9 in each group). Differences between the lean 
and obese groups were analysed by the unpaired Student’s t test or U of Mann Withney 
after testing the normality with the Kolmogorov–Smirnoff and Shapiro–Wilk tests. A P 
value <0.05 was considered statistically significant. The SPSS 14.0 version for 
WINDOWS (SPSS, Chicago, IL, USA) was used for the statistical analysis. 
 
RESULTS 
Subjects characteristics 
The goal of this study was to compare the gene expression pattern of two groups of 
subjects with similar habitual fat intake and moderate physical activity but with 
different susceptibility to weight gain. In fact, despite their habitual high fat intake 
during the last three years, a group of volunteers remained lean (BMI 23.10.4 kg/m2) 
so it was assumed that lean subjects were “resistant” to weight gain. Analysis of three-
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day weighed food records (Table 1) revealed that as designed, both groups (lean and 
obese) had a similar eating pattern with respect to the calorie intake and the energy 
distribution of macronutrients (carbohydrate, protein and fat). Thus, both groups 
reported a high percentage of fat in the diet (>40% of energy), with the same proportion 
of different types of dietary fat (saturated, monounsaturated and polyunsaturated). In 
addition, both groups reported no differences in the estimation of total METs (Table1).  
Gene expression profiles of obese compared to lean 
Table 2 and 3 show down-regulated and up-regulated genes involved in metabolic 
pathways in obese compared to lean subjects, respectively. The enrichment analysis, 
showed a downregulation of three catabolic pathways operating in the mitochondria, 
concerning fatty acid oxidation (P=0.008), tricarboxylic acid (TCA) cycle (P=0.001) 
and electron transport chain (P=0.012) which are closely related to the oxidative 
phosphorylation processes. In addition, we also found that genes regulating fatty acid 
biosynthesis (P=0.011) and glucose metabolism (P= 0.010) pathways were also 
downregulated in obese compared to lean subjects. 
Fatty acid β-oxidation cycle  
Our microarray data showed that transcripts for three of the six standard enzymes of the 
ß-oxidation cycle were downregulated in obese subjects: medium chain acyl-CoA 
dehydrogenases (ACADM), short chain enoyl-CoA hydratase (ECHS1), and short chain 
3-hydroxyacyl-CoA dehydrogenase (HADHSC). The downregulation of gene 
expression of ACADM and HADHSC was also verified by real-time PCR (Fig. 1A).  
TCA cycle  
Three transcripts encoding enzymes of the TCA cycle were downregulated in obese-
susceptible subjects: 1) citrate synthase (CS), one of the key regulatory enzymes that 
catalyze the condensation of oxaloacetate and acetyl coenzyme A to form citrate; 2) the 
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 subunit of the succinyl-CoA synthetase, ADP forming (SUCLA2) and 3)  subunit 
succinate-CoA ligase, GDP-forming (SUCLG2), two enzymes important to the 
metabolism of branched chain amino acids.  
Glyceroneogenesis  
Surprisingly, both the microarray data and the real-time PCR assessment ascertained 
that the expression of phosphoenolpyruvate carboxykinase (PCK1 also known as 
PEPCK), one of the important enzymes for glyceroneogenesis (GNG), was dramatically 
decreased in obese-susceptible subjects (Table 3; Figure 1B). Furthermore, the gene 
MCT2 encoding a high affinity pyruvate transporter (21) was also downregulated in 
obese compared to lean subjects. 
Electron transport and Oxidative phosphorylation  
Interestingly, our data showed that the expression of multiple components of the 
mitochondrial respiratory chain was reduced in obese individuals, including the electron 
transfer flavoprotein-ubiquinone oxidoreductase (ETFDH), which transfers the electrons 
generated by the ß-oxidation cycle to complex II of the oxidative phosphorylation 
system (OXPHOS), and the ALDH1L1 that catalyzes this reaction (Table 3; Figure 1A). 
The expression levels of UQCRC2 (a complex III component) and COX7C (a complex 
IV component), which catalyzes the electron transfer from reduced cytochrome c to 
oxygen were also reduced in obese subjects. Furthermore, the gene encoding F1-
ATPase assembly protein (ATPAF1) in human mitochondria was also downmodulated 
in obese subjects (Table 3).  
Fatty acid biosynthesis  
Several transcripts encoding for lipogenic enzymes were downregulated in obese 
subjects, including the transcript for ATP-citrate lyase (ACLY), the acetyl-Coenzyme A 
carboxylase beta (ACACB), the fatty acid synthase (FASN) and the stearoyl-CoA 
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desaturase 1 (SCD1). The down-regulation of FASN and SCD gene expression was also 
determined by real-time PCR (Fig. 1B) 
Glycolytic pathway  
The gene expression of critical regulators of glucose catabolism was downregulated in 
obese compared to lean subjects. Indeed, transcript levels for three out of eight 
glycolytic key enzymes were decreased in obese-susceptible subjects: 1) hexokinase 2 
(HK2), which encodes the enzyme that phosphorylates glucose to produce glucose-6-
phosphate, committing glucose to the glycolytic pathway; 2) fructose-2, 6-
bisphosphatase (PFKFB3), which encodes for an enzyme that is a potent activator of 
phosphofructokinase, a rate-limiting enzyme for glycolysis, and 3) glutamine-fructose-
6-phosphate transaminase 1 (GFPT1), the product of which is the first and rate-limiting 
enzyme of the hexosamine biosynthesis pathway (HBP).  
Amino acid (AA) degradation pathways 
Obesity susceptibility was also associated with a decreased expression of four 
transcripts coding for enzymes involved in AA degradation: 1) spermidine/spermine 
acetyltransferase 1 (SAT1), a rate-limiting enzyme in the catabolic pathway of 
polyamine metabolism 2) methylmalonyl CoA mutase (MUT) a transcript of the valine, 
leucine, and isoleucine degradation pathway; 3) one transcript encoding for glutamate-
ammonia ligase (GLUL), and 4) the aldehyde dehydrogenase 6 family, member A1 
(ALDH6A1), which encodes a enzyme that plays a role in the valine and pyrimidine 
catabolic pathways (Table 3).  
 
DISCUSSION 
In a previous study of our group, two groups of subjects with different susceptibility to 
high-fat induced weight gain were identified (25). In fact, despite having similar 
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habitual energy intake (with high proportion of energy as fat >40%) and similar patterns 
of physical activity, some volunteers were successfully “resistant” to weight gain. We 
hypothesised that the metabolic and hormonal mechanisms underlying the resistance to 
weight gain were probably genetically determined. As expected, the microarray analysis 
revealed a differential gene expression pattern in WAT of obese and lean high-fat 
consumers. The classification of genes differentially expressed in obese compared to 
lean subjects revealed an orchestrated downregulation of catabolic pathways operating 
in the mitochondria (fatty acid oxidation, TCA cycle and electron transport), with 
catabolic (glycolysis) and anabolic (glyceroneogenesis and lipogenesis) pathways of the 
cytoplasm.  
Interestingly, our data revealed that several transcripts encoding for key enzymes in the 
β-oxidation cycle and that multiple components of the mitochondrial respiratory chain 
were downregulated in obese subjects. Heilbronn et al (13) have demonstrated that 
different biomarkers of mitochondrial biogenesis and metabolism are reduced in 
overweight and obese insulin-resistant subjects. Two other studies using cDNA 
microarrays have reported that mitochondrial metabolism in both muscle and adipocytes 
is disturbed in subjects with insulin resistance, type 2 diabetes and even in subjects with 
family history for diabetes (28, 32). Both trials found a decrease in the expression of a 
subset of genes involved in mitochondrial oxidative metabolism, suggesting that 
impaired regulation of mitochondrial function could be an important mechanism linked 
to obesity and the metabolic syndrome. On the other hand, our data also showed that 
ATPAF1, which was reported as one of the assembly factors for the F1-ATPase in 
human mitochondria (37), was also downmodulated in obese subjects. Therefore, all the 
observed changes suggest that a decrease in both mitochondrial oxidative activity and 
mitochondrial adenosin triphosphate (ATP) synthesis could underlie the susceptibility to 
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HFD-induced obesity. This hypothesis is in agreement with the results obtained by Hao 
et al (12), which showed that mice with deleted PAS kinase (a cellular metabolic 
sensor) are resistant to high fat diet-induced obesity and insulin resistance, partly due to 
an increase in the rate of oxidative metabolism and ATP production. This finding could 
explain why after a high fat load of 50% of their energy requirements, obese-susceptible 
subjects were not able to increase their rates of fat oxidation more than the lean subjects, 
despite their higher metabolic mass (25). The previously reported similar rates of 
postprandial fat oxidation, together with the observed downregulation of genes involved 
in mitochondrial fatty acid oxidation and electron transport pathways suggest that 
obese-susceptible individuals may have a difficulty to properly adjust the amount of fat 
intake to the amount of fat oxidized. Similarly, another study, has observed an impaired 
capacity to regulate fat oxidation in the obese-insulin resistant state (4). Recently, the 
NUGENOB study has shown the importance of obesity-related polymorphisms in this 
area (8). 
Both theoretical aspect and experimental data from research on mitochondria indicate 
that cytosolic metabolism should be coordinated with mitochondrial metabolism so that 
both are oscillating in synchrony to permit the most efficient utilization of substrates 
resulting in energy production (ATP/ADP and NAD/NADH ratios) (11). In fact, 
glycolysis pathway generates cytoplasmic NADH, which is regenerated to NAD by the 
glycerol phosphate shuttle. Then, the electrons produced flow to Coenzyme Q, which 
has been shown by microarray to be downregulated in our obese-susceptible subjects. It 
can be speculated that this observation could explain the downregulation of transcripts 
encoding for enzymes of glycolyis pathway such as PFKFB3, which is highly expressed 
in adipose tissue and seems to exert a function that contributes to adiposity, but, on the 
other hand, protects against the inflammatory response of adipose tissue and the insulin 
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resistance induced by diet (16). Thus, the downregulation in gene transcripts involved in 
the glycolytic pathway in obese subjects is in agreement with and could explain the 
lower postpandrial carbohydrate oxidation that we observed in these obese-susceptible 
subjects (25). 
In vitro studies demonstrated that a decrease in mitochondrial ATP production resulted 
in the inhibition of FA synthesis (34). These data were corroborated by Kerner and 
Hopel (18), who demonstrated that cytosolic fatty acid synthesis and mitochondrial ß-
oxidation are the two pathways reciprocally regulated through the inhibitory effect of 
malonyl-CoA on CPT-1 activity. Recently, another investigation has proved that 
saturated fatty acids (like palmitic and stearic) are able of disrupting the mitochondrial 
function reducing ATP generation and the hyperpolarization of the mitochondria (15). 
Such data could explain the downregulation of key mediators of the fatty acid de novo 
biosynthesis pathway (FASN, SCD) in obese-susceptible subjects, which utilize the 
acetyl-CoA produced by the β-oxidation cycle to store energy for later use. As 
previously described, subjects with established obesity have an increased hepatic 
lipogenesis, but decreased lipogenic activity in adipose tissue (10). It has been 
suggested that the dysregulation of glyceroneogenesis (GNG) in WAT is a causal factor 
for obesity (3) and that a reduction in the expression of PCK1 (a key enzyme for GNG) 
and G6P, improved insulin sensitivity and glucose metabolism in mice (2). However, 
our data revealed that PCK1 was dramatically decreased in obese-susceptible subjects. 
This apparently surprising result is in agreement with a publication which shows that 
GNG in human SCAAT decreases with BMI in overweight women, suggesting that the 
decreased GNG in overweight people could participate in the metabolic syndrome 
appearance (20), in contrast, with another study which found that the expression of 
PCK1 mRNA was positively correlated with body fat in nondiabetic women (9). These 
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data imply that more research is needed in this area. Furthermore, in a previous study, 
we reported that obese-susceptible subjects exhibits a lower expression of the AQP7 
gene, encoding an aquaglyceroprotein, which could be implicated in the susceptibility to 
obesity by reducing glycerol release and promoting the accumulation of lipids in the 
adipose tissue (24). Therefore, the accumulation of glycerol due to the downregulation 
of AQP7 could be involved in the downregulation of PCK1 observed in obese-
susceptible subjects.  
Our data suggest that the differences in the metabolic adaptation to a high-fat 
diet consumption between lean and obese subjects could be the result of a coordinated 
down-regulation in the expression of mitochondrial genes encoding key proteins 
involved in fat oxidation and ATP production, and cytosolic genes involved in lipolytic 
and glycolytic pathways. This is consistent with the Neel’s thrifty genotype hypothesis, 
suggesting that in subjects genetically predisposed to obesity, a sustained increase in the 
high fat and energy intake may trigger biological actions leading to increase the 
efficiency of energy storage by limiting fuel oxidation and ATP production (31), by 
probably decreasing the expression of nuclear-encoded mitochondrial genes involved in 
oxidative metabolism. However, with the current data, it cannot be totally ruled out if 
the downregulation of these genes involved in oxidative metabolic pathways in obese 
subjects is a cause or a consequence of obesity, and more studies are needed to shed 
some light on this area. 
In summary, the higher expression levels in genes involved in oxidative 
metabolism in lean subjects as compared to obese, could contribute to their genetically 
mediated resistance to the development of obesity by a high fat diet suggesting a novel 
alternative therapeutical approach to be investigated. 
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Table 1. Body composition, metabolic rate, dietary assessment and physical activity pattern of lean-
resistant and obese-susceptible subjects participating in the study. 
 
 
Lean  
(n=9) 
Obese 
(n=9) 
P 
BMI 23.1±0.4 34.7±1.2 0.000 
Body fat (%) 14.4  0.9 29.8  1.2 0.000 
Total Energy intake (Kj/day) 11564±1081 11700±715 0.918 
    MUFA (E%) 26.9±1.3 25.5±1.7 0.554 
    SFA (E%) 12.1±0.9 10.4±0.5 0.124 
    PUFA (E%) 4.9±0.6 6.3±1.4 0.361 
    Complex CHO (E%) 17.4±1.9 18.4±2.1 0.722 
    Simple CHO (E%) 16.9±1.6 14.1±2.1 0.312 
    Protein (E%) 16.2±1.2 18.1±0.8 0.211 
RMR (KJ/min) 5.03  0.12 6.18  0.14 0.000 
Total activity (METs h/week) 146.0±10.4 168.9±10.1 0.141 
 
%E, percentage of energy; MUFA, monounsaturated fatty acid; SFA, saturated fatty acid; PUFA, polyunsaturated 
fatty acid; CHO, carbohydrate; RMR, resting metabolic rate; METs-h/wk, metabolic equivalents-hour per week, 
represent the ratio of energy expended during each specific activity to resting metabolic rate and are independent of 
body weight. 
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Table 2. Upregulated transcripts involved in metabolic pathways in subcutaneous abdominal adipose 
tissue (SCAAT) of obese-susceptible compared to lean-resistant subjects based on KEGG 
database. 
 Gene Symbol SLR SD Ref seq E.C nº 
Lipid Metabolism     
Arachidonic acid metabolism AKR1C3 0.88 0.32 NM_003739 1.1.1.188 
Metabolism of Cofactors and Vitamins     
Riboflavin metabolism ACP5 1.58 0.53 NM_001611 3.1.3.2 
Iron ion metabolism     
 FTL(1) 0.53 0.17 NM_000146  
 TFRC(1) 0.75 0.33 NM_003234  
 
SLR: Signal Log Ratio; SD: Standard deviation; EC: Enzyme compound; (1) classified by GO biological 
function criteria. AKR1C3: Aldo-keto reductase family 1 member C3. ACP5: acid phosphatase 5, tartrate 
resistant. FTL: Ferritin light chain; TFRC, transferrin receptor (p90, CD71). 
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Table 3. Downregulated transcripts involved in metabolic pathways in subcutaneous abdominal adipose 
tissue (SCAAT) of obese-susceptible compared to lean-resistant subjects based on KEGG 
database. 
Gene name Gene Symbol SLR SD Ref seq E.C 
Lipid Metabolism     
Fatty acid biosynthesis       
     Stearoyl-CoA desaturase-1 SCD1 -0.83 0.22 NM_005063 1.14.99.5
     Acetyl-CoA carboxylase  ACACB -0.43 0.53 NM_001093 6.4.1.2 
     Fatty acid synthase FASN -1.00 0.62 NM_012347 2.3.1.85 
Fatty acid  oxidation      
     Alcohol dehydrogenase 1B ADH1B -1.15 0.50 M21692 1.1.1.1 
     Medium chain acyl-CoA dehydrogenase ACADM -0.80 0.12 NM_000016 1.3.99.3 
     Long chain-fatty-acid-CoA ligase 1 ACSL1 -0.63 0.22 NM_001995 6.2.1.3 
     Short chain enoyl-CoA hydratase, , 1 ECHS1 -0.48 0.26 NM_004092 4.2.1.17 
     3-hydroxyacyl-CoA dehydrogenase HADHSC -1.00 0.44 NM_005327 1.1.1.35 
Citrate cycle (TCA cycle)     
      subunit of the succinyl-CoA synthetase, ADP-forming  SUCLA2 -0.50 0.37 NM_003850 6.2.1.5 
      subunit succinate-CoA ligase, GDP-forming SUCLG2 -0.38 0.38 NM_003848 6.2.1.4 
     Citrate synthase CS -0.68 0.26 NM_004077 2.3.3.1 
     ATP-citrate lyase ACLY -0.35 0.10 NM_001096 2.3.3.8 
     Phosphoenolpyruvate carboxykinase 1 (also PEPCK) PCK1 -1.78 0.73 NM_002591 4.1.1.32 
     Monocarboxylate Transporter 2 MCT2(2) -0.70 0.29 AF049608  
Electron transport and Oxidative  
Phosphorylation Pathways     
     Electron transfer flavoprotein-ubiquinone oxidoreductase ETFDH -0.95 0.25 NM_004453 1.5.5.1 
     Aldehyde dehydrogenase 1 family, member L1 ALDH1L1(1) -1.15 0.85 NM_012190 1.5.1.6 
     Cytochrome c oxidase subunit 7C COX7C -0.72 0.22 NM_001867 1.9.3.1 
     Cytochromes b5 CYB5(1) -1.35 0.62 M22976  
     Cytochrome P450 26B1 CYP26B1(1) -0.40 0.26 NM_019885  
     Cytochrome b-c1 complex subunit 2 UQCRC2 -0.45 0.19 NM_003366  
     F1-ATPase assembly protein factor 1 ATPAF1(2) -0.60 0.58 NM_022745 1.10.2.2 
Carbohydrate Metabolism     
Glycolysis       
     Fructose-2, 6-bisphosphatase PFKFB3 -0.93 0.51 NM_004566 3.1.3.11 
     Hexokinase 2 HK2 -0.83 0.79 NM_000189 2.7.1.1 
Aminosugars metabolism        
     Glutamine-fructose-6-phosphate transaminase 1 GFPT1 -0.38 0.05 NM_002056 2.6.1.16 
Pentose and glucuronate interconversions       
     Dicarbonyl/L-xylulose reductase DCXR -0.38 0.05 NM_016286 1.1.1.10 
Amino Acid Metabolism     
Arginine and proline metabolism        
     Spermidine/spermine acetyltransferase 1 SAT1 -0.55 0.10 NM_002970 2.3.1.57 
     High-mobility group box 2 HMGB2 -0.28 0.17 NM_002129 4.1.1.50 
Glutamate metabolism        
     Glutamate-ammonia ligase (also GS) GLUL -0.68 0.05 AL161952 6.3.1.2 
Valine, leucine and isoleucine degradation        
     Aldehyde dehydrogenase 6 family, member A1 ALDH6A1 -0.68 0.59 NM_005589 1.2.1.27 
     Methylmalonyl CoA mutase MUT -0.80 0.73 NM_000255 5.4.99.2 
Nitrogen metabolism        
     Carbonic anhydrase III CA3 -2.05 0.77 NM_005181 4.2.1.1 
Metabolism of Cofactors and Vitamins     
Pantothenate and CoA biosynthesis        
     Dihydropyrimidine dehydrogenase DPYD -0.35 0.10 NM_000110 1.3.1.2 
Iron ion metabolism(2)     
Iron transport      
     Transferrin TF(1) -1.35 0.86 NM_001063  
SLR: Signal Log Ratio; SD: Standard Deviation; EC: Enzyme compound ; (1) classified by GO biological 
function criteria; (2) classified by findings in literature. 
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Legends to the figures 
 
Fig. 1. mRNA expression by TaqMan real-time quantitative PCR of differentially 
expressed genes identified by microarray. A) Genes encoding key enzymes in -
oxidation and electron transport. B) Genes encoding enzymes in Lipogenesis and TCA 
pathways in SCAAT adipose tissue of lean and obese high fat intakers; n=9 in each 
group. Data (means ± SEM) were calculated by the 2 -ΔΔCt method (mean value for lean 
subjects was set at 1) and were analyzed at ΔCT stage to exclude potential bias because 
of averaging data that had been transformed through the equation 2 -ΔΔCt. Human18S 
rRNA was used as reference to normalize the expression levels. * P < 0.05;**P < 0.01 
lean    , vs. obese    subjects. ACADM: medium chain acyl-CoA dehydrogenase. HADHSC: 3-
hydroxyacyl-CoA dehydrogenase. ALDH1L1: aldehyde dehydrogenase 1 family, member L1. ETFDH: 
Electron transfer flavoprotein-ubiquinone oxidoreductase. FASN: Fatty acid synthase. SCD1: Stearoyl-
CoA desaturase-1. PCK1: Phosphoenolpyruvate carboxykinase 1. 
 
Fig. 2. Schematic representation of the main energy metabolic pathways that may lead 
to obesity. Enzymes/Receptors in boxes are those that are encoded by genes 
differentially regulated in obese-susceptible compared to lean-resistant subjects (see text 
for references); *mRNA expression was verified by real-time PCR.  
The results of the microarrays show that the differences in the metabolic adaptation to a 
high fat diet between resistant-lean and obese-susceptible subjects could be the result of 
a coordinated down-regulation in the expression of mitochondrial genes encoding key 
proteins involved in fat oxidation and ATP production. As both, cytosolic and 
mitochondrial metabolisms are coordinated oscillating in synchrony resulting in energy 
production of the ATP/ADP and NAD/NADH ratios for the required reducing potential. 
The downregulation of the electron transport pathway will lead to the downregulation of 
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cytosolic genes involved in lipolytic and glycolytic pathways. Furthermore, adipose 
tissue seems to trigger defense mechanisms against fat deposition by downregulating 
glyceroneogenesis and lipogenesis pathways. Abbreviations: G, Glucose; F, Fructose; P, 
phosphate; GAP, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone phosphate; 
G3P, glycerol-3-phosphate; PEP, phosphoenolpyruvate; OAA, oxalacetate; A-CoA, 
Acyl-CoA; T-2-E-CoA, Trans 2-Enoil-CoA; 3-L-OH-A-CoA, 3-L-Hydroxy-Acyl-
CoA; 3-K.A-CoA, 3-Ketoacyl-CoA.  
 
